MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy
NCT ID: NCT05555537
Last Updated: 2022-10-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
90 participants
OBSERVATIONAL
2022-11-01
2024-11-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Early detection of the prognosis might help in guiding patients for proper management and treatment strategy.
This may open the door for new drug trials.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Circulating microRNAs as Biomarkers of RESPIratory Dysfunction in Patients With Refractory epilePSY
NCT03419000
Genetic Diagnosis and Personalized Medicine for Patients With Epilepsy
NCT06321822
MiCrobiota-gut-brain Axis in Resistant Epilepsy
NCT07010445
Study of Predictors of Response to Anti Epilepsy in Epilepsy
NCT02883712
Genetic and Electrophysiologic Study in Focal Drug-resistant Epilepsies
NCT02890641
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
MiRNAs are small noncoding RNAs that span between 19 and 24 nucleotide bases((2).They gain biological activity through base pairing in the 30-untranslated regions of target messenger RNA (mRNA) , thereby guiding a protein complex termed the RNA-induced silencing complex (RISC) that bind to the mRNA sequence and results in either the inhibition of translational processes or the degradation of the mRNA (3). Dysregulated miRNA expression has been associated with inflammatory pathways, cell death, neuronal excitability, and synaptic reorganization, which underlie epileptogenesis (4).
High- mobility group box 1(HMGB1) is a chromatin component that is physiologically attached to nuclei. However, following CNS insult, it can promptly be migrated towards cytoplasm and is discharged extracellularly. HMGB1mediates sterile neuro-inflammation evoked by epileptogenic injury and recurrent seizures(5) .HMGB1 increases in neurons, glia, and endothelial cells of the blood brain barrier (BBB) in DRE.
The HMGB1 contributes to the overexpression of P-glycoprotein, a BBB protein, which is induced in DRE foci and extrudes various ASMs from the brain(6) .
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Drug resistant epilepsy
failure to achieve sustained seizure freedom after adequate and well tolerated trials of two antiseizure medications
MiRNA223 and High mobility group box1(HMGB1)
Measure tye 2 biomarkers miRNA223 and HMGB1 in drug resistant and in medically controled epilepsy
Medically controled epilepsy
seizure freedom for at least the last 6months) matched in sex and age.
MiRNA223 and High mobility group box1(HMGB1)
Measure tye 2 biomarkers miRNA223 and HMGB1 in drug resistant and in medically controled epilepsy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MiRNA223 and High mobility group box1(HMGB1)
Measure tye 2 biomarkers miRNA223 and HMGB1 in drug resistant and in medically controled epilepsy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Control group: patients diagnosed as medically controlled epilepsy
Exclusion Criteria
* Alzheimers disease
* Parkinsons disease
* amyotrophic lateral sclerosis
* major depression disorder
* Non neurological criteria: tumors and cardiovascular
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Safaa Ali Samir Hussien Mohamed
Assistant lecture
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
drug resistant epilepsy
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.